Daniel A. Haber, M.D., Ph.D., is director of the Massachusetts General Hospital Cancer Center and the Isselbacher/Schwartz professor of oncology at Harvard Medical School. Haber attended college at Massachusetts Institute of Technology. He received his medical and doctoral degrees at Stanford in 1983, completed an internal medical residency at Massachusetts General Hospital, clinical oncology training at Dana Farber Cancer Institute, and a postdoctoral research fellowship at MIT, joining the Harvard Medical School faculty in 1991 as assistant professor at the MGH Cancer Center.
Haber’s laboratory interests have focused on the area of cancer genetics, including the etiology of the pediatric kidney cancer Wilms tumor and genetic predisposition to breast cancer. In collaboration with MGH Bioengineering Professor Mehmet Toner, Ph.D., Haber’s group has recently established the application of a novel microfluidic technology for quantifying and purifying rare circulating tumor cells from the blood of patients with various epithelial cancers. The further development and clinical application of this nanotechnology constitutes the basis for the proposal supported by Stand Up To Cancer.
Haber is on the editorial boards of Cell and Cancer Cell, and has served as genetics editor for the New England Journal of Medicine. He has been elected to the American Association of Physicians, the American Society for Clinical Investigation, and the board of directors of the American Association for Cancer Research. Haber has been honored with the Doris Duke Distinguished Clinical Scholar Award and a Professorship from the National Foundation for Cancer Research, a MERIT Award from the National Cancer Institute, a Dream Team Award from the Prostate Cancer Foundation, the Emil Freireich Award from M. D. Anderson Cancer Center, the Sternlicht Award from Case Western Reserve, and the Hinda Rosenthal Award for Translational Research from AACR. He was appointed to the Howard Hughes Medical Institute in 2008.